ClinicalTrials.gg
CompletedNCT01708564rhFVIIaUpdated Jul 30, 2013

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B

A Phase 1 interventional study of rhFVIIa in Hemophilia, sponsored by rEVO Biologics. Completed at 3 sites in 2 countries. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-30.

Sponsored by rEVO Biologics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
14th of 19
15 · median 24
Started
2012
the only one that year
Phase 1
7 of 20
none open now
Registered
14th of 20
by date
Lead sponsor
2 of 20
rEVO Biologics

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 1, and was the 14th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

This study will assess the pharmacokinetics and pharmacodynamics of rhFVIIa at three dose levels. The results will help identify the most optimal doses to take forward to the Phase 2/3 studies where bleedings in hemophilia patients with inhibitors will be treated with rhFVIIa.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. be male with a diagnosis of moderate or severe congenital hemophilia A and/or B (with or without inhibitors)
  2. be 18 years or older, up to and including 75 years of age
  3. be capable of understanding and willing to comply with the conditions of the protocol
  4. have read, understood and provided written

Exclusion criteria

Exclusion Criteria:

  1. have any coagulation disorder other than hemophilia A or B
  2. have a body weight >105 kg (231 lb)
  3. be immuno-suppressed (i.e., the patient should not receive systemic medication \<30 days prior to enrollment, at screening should be >200/µl)
  4. have a known allergy or to rabbits
  5. have count \<100,000/mL
  6. have had within one month prior to first administration of the study drug in this study a major surgical procedure (e.g. orthopedic, abdominal)
  7. have an active, ongoing bleeding for which the patient is being treated, or treatment for a bleeding was stopped within 24 hours of the time of study drug administration
  8. have received a Factor VII or FVIIa containing product (either plasma derived or recombinant) within 72 hours prior to any study drug administration
  9. have received an drug within 30 days of the first study drug administration, or is expected to receive such drug during participation in this study
  10. have a hepatic (hepatic enzymes >3 times the ) and/or renal impairment (creatinine >2 times the upper limit of normal)
  11. have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, , deep venous thrombosis or pulmonary embolism) within 2 years prior to first dose of study drug, have an arterial stent in place or have clinically significant atherosclerotic disease (e.g., angina pectoris, peripheral vascular disease)
  12. use any anticoagulant for arterial/venous obstructions and/or atrial fibrillation within 7 days prior to first study drug administration
  13. have an active (those with non-melanoma skin cancer are allowed)
  14. have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Cohort 1

    10 patients administered a single low dose of rhFVIIa

    Biological: rhFVIIa

  • Experimental
    Cohort 2

    10 patients administered a single intermediate dose of rhFVIIa

    Biological: rhFVIIa

  • Experimental
    Cohort 3

    10 patients administered a single high dose of rhFVIIa

    Biological: rhFVIIa

Interventions

  • BiologicalrhFVIIa

    Patients will be administered low, intermediate and high doses of rhFVIIa

    Also known as: Coagulation Factor VIIa (Recombinant)

06

What researchers measure

Primary outcomes

  1. Factor VIIa concentration in patient plasma as measured by FVIIa PK and PD assays

    Time frame: Up to 36 hours of dosing

Secondary outcomes

  1. Incidence of patients with treatment emergent adverse events

    Time frame: Up to 28 days after dosing

07

Study locations

3 sites
  • UC Davis Health System Internal Medicine: Hematology & Oncology
    Sacramento, California 95817, United States
  • RUSH Hemophilia & Thrombophilia Center
    Chicago, Illinois 60612, United States
  • Centre for Human Drug Research
    Leiden, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2012
First posted
Oct 17, 2012
Start
Oct 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Jul 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01708564
Lead sponsor
rEVO Biologics
Responsible party
Sponsor
First posted
Oct 17, 2012
Start date
Oct 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Jul 30, 2013

Study contacts

Johan Frieling, MD,PhD
study director · rEVO Biologics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion